Status:
COMPLETED
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
Lead Sponsor:
Pfizer
Conditions:
Overweight
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics fol...
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 18 and 55 years
- Body Mass Index (BMI) of approximately 27 to 35 kg/m2; and a total body weight \>50 kg (110 lbs)
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00799006
Start Date
November 1 2008
End Date
June 1 2009
Last Update
July 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511